Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Protein engineering, design & selection : PEDS

• Publication date

  2010-07-01

• Fields of study

  Medicine, Chemistry, Engineering

• Identifiers
  DOI 10.1093/protein/gzq028PMID 20457695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural understanding of stabilization patterns in engineered bispecific Ig‐like antibody molecules

  2009cited by this paper
• Rapid screening platform for stabilization of scFvs in Escherichia coli.

  2009cited by this paper
• Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

  2009cited by this paper
• Conserved amino acid networks involved in antibody variable domain interactions

  2009cited by this paper
• Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

  2009cited by this paper
• The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.

  2009cited by this paper
• A broad range of Fab stabilities within a host of therapeutic IgGs.

  2007cited by this paper
• Bispecific Antibodies: Molecules That Enable Novel Therapeutic Strategies

  2007cited by this paper
• Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression.

  2006cited by this paper
• Recombinant bispecific antibodies for cancer therapy

  2005cited by this paper
• Engineered antibody fragments and the rise of single domains

  2005cited by this paper
• Recombinant approaches to IgG-like bispecific antibodies

  2005cited by this paper
• A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity*

  2005cited by this paper
• Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions.

  2005cited by this paper
• Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C.

  2004cited by this paper
• Aggregation-resistant domain antibodies selected on phage by heat denaturation

  2004cited by this paper
• Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C

  2004cited by this paper
• Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences.

  2004cited by this paper
• A graph‐theory algorithm for rapid protein side‐chain prediction

  2003cited by this paper
• A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity.

  2003influential reference
• Biophysical properties of human antibody variable domains.

  2003cited by this paper
• Stability engineering of antibody single-chain Fv fragments.

  2001cited by this paper
• Directed evolution of a stable scaffold for T-cell receptor engineering

  2000cited by this paper
• In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain.

  2000cited by this paper
• Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 region

  1999cited by this paper
• One Hundred Seventy-Fold Increase in Excretion of an FV Fragment-Tumor Necrosis Factor Alpha Fusion Protein (sFV/TNF-α) fromEscherichia coli Caused by the Synergistic Effects of Glycine and Triton X-100

  1998cited by this paper
• Structure and stability of the N-terminal domain of the ribosomal protein L9: evidence for rapid two-state folding.

  1998cited by this paper
• Structural determinants in the sequences of immunoglobulin variable domain.

  1998cited by this paper
• Design and production of novel tetravalent bispecific antibodies

  1997cited by this paper
• Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments

  1996cited by this paper
• Denaturant m values and heat capacity changes: Relation to changes in accessible surface areas of protein unfolding

  1995cited by this paper
• Comparative protein modelling by satisfaction of spatial restraints.

  1993cited by this paper
• Structural energetics of the molten globule state

  1993cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• A comparison of strategies to stabilize immunoglobulin Fv-fragments.

  1990cited by this paper
• CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

  1983cited by this paper

• Application of nanobody-based CAR-T in tumor immunotherapy (Review)

  2025cites this paper
• EGFRvIII-Targeted Virus-Like Particles Enable Selective Genome Editing and Elimination of Glioblastoma Cells

  2025cites this paper
• Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA

  2025cites this paper
• Enhanced Neutralization of Japanese Encephalitis Virus Using an Engineered VL Double-Domain

  2025cites this paper
• Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience

  2025cites this paper
• The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells.

  2025cites this paper
• Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence

  2025cites this paper
• Design and engineering of bispecific antibodies: insights and practical considerations

  2024cites this paper
• Developability considerations for bispecific and multispecific antibodies

  2024cites this paper
• A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications

  2024cites this paper
• Molecular Dynamics-Based Design and Biophysical Evaluation of Thermostable Single-Chain Fv Antibody Mutants Derived from Pharmaceutical Antibodies

  2023cites this paper
• Recent research advances on non-linear phenomena in various biosystems.

  2023cites this paper
• Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data

  2023cites this paper
• Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features

  2023cites this paper
• Next generation of multispecific antibody engineering.

  2023cites this paper
• Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A

  2023cites this paper
• Antibody-receptor bioengineering and its implications in designing bioelectronic devices.

  2022cites this paper
• Towards generalizable prediction of antibody thermostability using machine learning on sequence and structure features

  2022cites this paper
• Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies

  2022cites this paper
• Nuevas Opciones de Anti-VEGF Aprobados por la FDA para el Manejo de la Degeneración Macular Húmeda Asociada a la Edad

  2022cites this paper
• The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration

  2022cites this paper
• Differential scanning fluorimetry as a measure of functionality of refolded anti-malarial antibody fragments

  2022cites this paper
• Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics

  2021cites this paper
• Preparation of Anti Toll-Like Receptor-4 Nano-Antibody and Its Effect on Gram Negative Sepsis.

  2021cites this paper
• Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors

  2021cites this paper
• Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling

  2021cites this paper
• Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors

  2021cites this paper
• Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): An in silico and in vitro study

  2021cites this paper
• Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.

  2021cites this paper
• Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires

  2021cites this paper
• Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods

  2021cites this paper
• Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors

  2021cites this paper
• Non-Antibody-Based Binders for the Enrichment of Proteins for Analysis by Mass Spectrometry

  2021cites this paper
• Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms

  2020cites this paper
• Chapter 5: Lessons Learned in Understanding Dual Variable Domain-Ig (DVD-Ig) Structural Complexity to Select DVD-Ig Lead and Therapeutic Candidates

  2020cites this paper
• Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

  2020cites this paper
• Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding

  2020cites this paper
• Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

  2020cites this paper
• A Generic Procedure for the Isolation of pH- and Magnesium-Responsive Chicken scFvs for Downstream Purification of Human Antibodies

  2020cites this paper
• Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences

  2020cites this paper
• Hurdles in Cancer Immunotherapy

  2020cites this paper
• Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

  2019cites this paper
• Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies

  2019cites this paper
• Building blocks for bispecific and trispecific antibodies.

  2019cites this paper
• Design and Production of Bispecific Antibodies

  2019influential citation
• HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

  2019cites this paper
• Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics

  2019cites this paper
• UNDERSTANDING THE RELATIONSHIP BETWEEN BISPECIFIC ANTIBODY DESIGN AND FUNCTION: HOW VALENCY AND SPATIAL CONFIGURATION CAN IMPROVE ANTI-TUMOR RESPONSES

  2019cites this paper
• Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

  2018cites this paper
• A Highly Sensitive Detection System based on Proximity-dependent Hybridization with Computer-aided Affinity Maturation of a scFv Antibody

  2018cites this paper
• Strategies to Address Chimeric Antigen Receptor Tonic Signaling

  2018cites this paper
• Parallel Evolution of Antibody Affinity and Thermal Stability for Optimal Biotherapeutic Development.

  2018cites this paper
• Camelid Single-Domain Antibodies (VHHs) against Crotoxin: A Basis for Developing Modular Building Blocks for the Enhancement of Treatment or Diagnosis of Crotalic Envenoming

  2018cites this paper
• Bispecific Antibodies: Formats and Areas of Application

  2018cites this paper
• Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies

  2018cites this paper
• Novel Technologies for Generation of Bispecific Constructs

  2018cites this paper
• Development of a Nanobody-Based Competitive Dot ELISA for Visual Screening of Ochratoxin A in Cereals

  2017cites this paper
• The making of bispecific antibodies

  2017cites this paper
• Driving Forces for Nonnative Protein Aggregation and Approaches to Predict Aggregation-Prone Regions.

  2017cites this paper
• A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6

  2017cites this paper
• Decomposing Dynamical Couplings in Mutated scFv Antibody Fragments into Stabilizing and Destabilizing Effects.

  2017cites this paper
• Bispecific antibodies for viral immunotherapy

  2017cites this paper
• Proofreading of substrate by the Escherichia coli Twin Arginine Translocase

  2017cites this paper
• Defining the mechanism behind the self-association of therapeutic monoclonal antibodies using mass spectrometric techniques

  2016cites this paper
• Mutations in Antibody Fragments Modulate Allosteric Response Via Hydrogen-Bond Network Fluctuations.

  2016cites this paper
• Engineering antibody therapeutics.

  2016cites this paper
• Modulating non-native aggregation and electrostatic protein-protein interactions with computationally designed single-point mutations.

  2016cites this paper
• Investigation into the major surface proteases of African trypanosomes.

  2016cites this paper
• Developing antibody discovery and recombination technology towards the goal of modulating cation channels

  2016cites this paper
• Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex*

  2016cites this paper
• OCoM-SOCoM: Combinatorial Mutagenesis Library Design Optimally Combining Sequence and Structure Information

  2016cites this paper
• Comparing domain interactions within antibody Fabs with kappa and lambda light chains

  2016cites this paper
• Activity-based assessment of an engineered hyperthermophilic protein as a capture agent in paper-based diagnostic tests.

  2016cites this paper
• Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

  2016cites this paper
• Development of a nanobody-alkaline phosphatase fusion protein and its application in a highly sensitive direct competitive fluorescence enzyme immunoassay for detection of ochratoxin A in cereal.

  2015cites this paper
• A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation

  2015cites this paper
• A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv)*

  2015cites this paper
• Advances in Antibody Design.

  2015cites this paper
• Protein Engineering: Applications to Therapeutic Proteins and Antibodies

  2015cites this paper
• Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.

  2015cites this paper
• Structure‐based design of combinatorial mutagenesis libraries

  2015cites this paper
• Identification of optimal protein binders through the use of large genetically encoded display libraries.

  2015cites this paper
• Redistribution of Flexibility in Stabilizing Antibody Fragment Mutants Follows Le Châtelier’s Principle

  2014influential citation
• Antibody variable domain interface and framework sequence requirements for stability and function by high-throughput experiments.

  2014influential citation
• OptMAVEn – A New Framework for the de novo Design of Antibody Variable Region Models Targeting Specific Antigen Epitopes

  2014cites this paper
• Development trends for generation of single-chain antibody fragments

  2014cites this paper
• Nanocell targeting using engineered bispecific antibodies

  2014cites this paper
• Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity

  2014cites this paper
• Structural insights and biomedical potential of IgNAR scaffolds from sharks

  2014cites this paper
• Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.

  2014cites this paper
• An in vivo platform for identifying protein aggregation inhibitors

  2014cites this paper
• Loop-sequence features and stability determinants in antibody variable domains by high-throughput experiments.

  2014cites this paper
• Heat-induced Irreversible Denaturation of the Camelid Single Domain VHH Antibody Is Governed by Chemical Modifications

  2014cites this paper
• Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.

  2014cites this paper
• Chemical Modifications the Camelid Single Domain VHH Antibody Heat-induced Irreversible Denaturation of Protein Structure and Folding :

  2014cites this paper
• Thermodynamic stability and flexibility characteristics of antibody fragment complexes.

  2013cites this paper
• The intriguing options of multispecific antibody formats for treatment of cancer.

  2013cites this paper
• Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments

  2013cites this paper
• CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery

  2013cites this paper
• Toward aggregation-resistant antibodies by design.

  2013cites this paper